Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

207
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
207
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

182
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
182
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

159
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Efficacy of Combined Iliac Crest Bone Graft and Recombinant Human Bone Morphogenetic Protein for Alveolar Bone Grafting.

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2026
Same author

Functional Outcomes in Patients with Hand Burns Receiving Long-Term Occupational Hand Therapy: A Burn Unit's 10-Year Experience.

Journal of burn care & research : official publication of the American Burn Association·2026
Same author

Incidence and Predictors of Symptomatic Retroperitoneal Fluid Collection Following Anterior Lumbar Interbody Fusion.

Global spine journal·2026
Same author

Oral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

This is not an operation: Limits of virtual training in plastic surgery.

American journal of surgery·2026
Same author

Algorithm-Based Reconstruction for Pediatric Mandibular Desmoid Tumors: Two Decades From a Single Institution.

The Journal of craniofacial surgery·2026

Related Experiment Video

Updated: Jun 12, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

194

Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons.

Eloise W Stanton, Artur Manasyan1, Rakhi Banerjee1

  • 1From the Keck School of Medicine, University of Southern California, Los Angeles, CA.

Annals of Plastic Surgery
|September 18, 2024
PubMed
Summary

Glucagon-like peptide-1 (GLP-1) agonists aid weight loss and glycemic control, potentially benefiting plastic surgery patients. Careful consideration of risks like aspiration is crucial for safe integration into perioperative care.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K
Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K

Related Experiment Videos

Last Updated: Jun 12, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

194
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K
Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

23.5K

Area of Science:

  • Endocrinology and Metabolism
  • Plastic Surgery
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) agonists are established treatments for type 2 diabetes, offering benefits in insulin release, glucagon suppression, and glucose metabolism.
  • These agents also promote weight reduction and improve cardiovascular health, suggesting broader therapeutic applications.
  • Their potential role in perioperative weight management and glycemic control presents opportunities within plastic surgery.

Purpose of the Study:

  • To review the utilization of GLP-1 agonists in plastic surgery.
  • To evaluate their benefits and limitations in perioperative weight management and glycemic control.
  • To assess their impact on surgical candidacy and outcomes.

Main Methods:

  • Comprehensive literature review of relevant studies, meta-analyses, and clinical trials.
  • Analysis focused on weight reduction, glycemic control, cardiovascular risk factors, and potential complications.
  • Evaluation of GLP-1 agonists' efficacy and safety in surgical contexts.

Main Results:

  • GLP-1 agonists demonstrate efficacy in weight management and glycemic control, with significant HbA1c reductions observed with high-dose semaglutide and tirzepatide.
  • Potential benefits include expanded surgical candidacy and improved outcomes for procedures like breast reconstruction and lymphedema management.
  • Concerns include gastrointestinal side effects, pancreatitis, bowel obstruction, venous thromboembolism, and delayed gastric emptying, necessitating careful risk assessment.

Conclusions:

  • GLP-1 agonists offer advantages for perioperative weight management and glycemic control in plastic surgery.
  • They may enhance surgical candidacy and mitigate lymphedema risk but require careful management of complications, especially aspiration risk.
  • Further research is needed to optimize their integration into plastic surgery protocols and enhance patient care.